{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:11:55Z","timestamp":1790435515016,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.therap.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T11:59:46Z","timestamp":1541678386000},"page":"271-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Pharmacoepidemiology of non-steroidal anti-inflammatory drugs"],"prefix":"10.1016","volume":"74","author":[{"given":"Nicholas","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem Ezgi","family":"Gulmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Droz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.therap.2018.11.002_bib0355","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.therap.2018.11.002_bib0360","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1163\/156856003322699537","article-title":"Place of OTC analgesics and NSAIDs in osteoarthritis","volume":"11","author":"Moore","year":"2003","journal-title":"Inflammopharmacology"},{"issue":"8","key":"10.1016\/j.therap.2018.11.002_bib0365","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/pds.1388","article-title":"Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study","volume":"16","author":"Depont","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.therap.2018.11.002_bib0370","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5414\/CPP42415","article-title":"Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting","volume":"42","author":"Hasford","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2018.11.002_bib0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00044011-199918020-00001","article-title":"The PAIN study: Paracetamol: Aspirin and Ibuprofen New tolerability study. A large scale randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia","volume":"18","author":"Moore","year":"1999","journal-title":"Clin Drug Invest"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0380","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2515\/therapie:2004092","article-title":"NSAID use profiles derived from reimbursement data in France","volume":"59","author":"Moore","year":"2004","journal-title":"Therapie"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0385","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bcp.12239","article-title":"Usage patterns of \u201cover-the-counter\u201d vs. prescription-strength non-steroidal anti-inflammatory drugs in France","volume":"77","author":"Duong","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2018.11.002_bib0390","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.12957","article-title":"Usage patterns of paracetamol in France","volume":"82","author":"Duong","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.therap.2018.11.002_bib0395","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.therap.2018.11.002_bib0400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40264-012-0013-7","article-title":"Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study","volume":"36","author":"Gulmez","year":"2013","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.therap.2018.11.002_bib0405","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/pds.3371","article-title":"Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France","volume":"22","author":"Moore","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0410","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0","article-title":"Large scale safety study of Ketoprofen 25mg (Toprec\u00ae) in febrile and painful conditions","volume":"5","author":"Moore","year":"1996","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2018.11.002_bib0415","first-page":"CD008659","article-title":"Single dose oral analgesics for acute postoperative pain in adults \u2013 an overview of Cochrane reviews","volume":"9","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.therap.2018.11.002_bib0420","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s10194-016-0703-0","article-title":"Network meta-analysis of migraine disorder treatment by NSAIDs and triptans","volume":"17","author":"Xu","year":"2016","journal-title":"J Headache Pain"},{"issue":"10090","key":"10.1016\/j.therap.2018.11.002_bib0425","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(17)31744-0","article-title":"Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis","volume":"390","author":"da Costa","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.therap.2018.11.002_bib0430","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/ebmed-2017-110878","article-title":"NSAIDs are superior to paracetamol for osteoarthritic pain and function in a network meta-analysis","volume":"23","author":"Rasmussen","year":"2018","journal-title":"BMJ Evid Based Med"},{"issue":"10033","key":"10.1016\/j.therap.2018.11.002_bib0435","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(15)01170-8","article-title":"Does paracetamol still have a future in osteoarthritis?","volume":"387","author":"Moore","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2018.11.002_bib0440","first-page":"CD012638","article-title":"Oral non-steroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults","volume":"7","author":"Derry","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2018.11.002_bib0445","first-page":"CD012637","article-title":"Oral paracetamol (acetaminophen) for cancer pain","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2018.11.002_bib0450","first-page":"CD012537","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents","volume":"8","author":"Eccleston","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2018.11.002_bib0455","first-page":"CD012563","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents","volume":"7","author":"Cooper","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7046","key":"10.1016\/j.therap.2018.11.002_bib0460","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","article-title":"Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis","volume":"312","author":"Henry","year":"1996","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.therap.2018.11.002_bib0465","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.therap.2018.11.002_bib0470","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.therap.2018.11.002_bib0475","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1053\/j.gastro.2004.07.010","article-title":"Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial","volume":"127","author":"Chan","year":"2004","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1016\/j.therap.2018.11.002_bib0480","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis","volume":"347","author":"Chan","year":"2002","journal-title":"N Engl J Med"},{"issue":"9736","key":"10.1016\/j.therap.2018.11.002_bib0485","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","article-title":"Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial","volume":"376","author":"Chan","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.therap.2018.11.002_bib0490","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2125.2009.03588.x","article-title":"Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users","volume":"69","author":"Laharie","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2018.11.002_bib0495","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00042737-200012020-00007","article-title":"Epidemiology and course of acute upper gastrointestinal haemorrhage in four French geographical areas","volume":"12","author":"Czernichow","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.therap.2018.11.002_bib0500","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00044011-200727030-00002","article-title":"Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety","volume":"27","author":"Moore","year":"2007","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.therap.2018.11.002_bib0505","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.842","article-title":"Risk factors for adverse events in analgesic drug users: results from the PAIN study","volume":"12","author":"Moore","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.therap.2018.11.002_bib0510","first-page":"2226","article-title":"Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis","volume":"30","author":"Fries","year":"2003","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.therap.2018.11.002_bib0515","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/00325481.2018.1429793","article-title":"Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics","volume":"130","author":"Moore","year":"2018","journal-title":"Postgrad Med"},{"issue":"11","key":"10.1016\/j.therap.2018.11.002_bib0520","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-018-0686-7","article-title":"Coronary events after dispensing of ibuprofen: a propensity score matched cohort study versus paracetamol in the French nationwide claims database sample","volume":"41","author":"Duong","year":"2018","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.therap.2018.11.002_bib0525","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11938-014-0029-4","article-title":"Prevention and treatment of NSAID Gastropathy","volume":"12","author":"Gargallo","year":"2014","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"9458","key":"10.1016\/j.therap.2018.11.002_bib0530","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","article-title":"Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study","volume":"365","author":"Graham","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.therap.2018.11.002_bib0535","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"issue":"9894","key":"10.1016\/j.therap.2018.11.002_bib0540","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.therap.2018.11.002_bib0545","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","article-title":"Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population","volume":"52","author":"Garcia Rodriguez","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2018.11.002_bib0550","doi-asserted-by":"crossref","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0555","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/14740338.2014.907792","article-title":"Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies","volume":"13","author":"Salvo","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.therap.2018.11.002_bib0560","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1517\/14740338.2014.846324","article-title":"Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC","volume":"13","author":"Moore","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"25","key":"10.1016\/j.therap.2018.11.002_bib0565","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"issue":"9357","key":"10.1016\/j.therap.2018.11.002_bib0570","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.therap.2018.11.002_bib0575","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.ATV.3.4.383","article-title":"Ibuprofen protects plateletcyclo-oxygenase from irreversible inhibition by aspirin","volume":"3","author":"Rao","year":"1983","journal-title":"Arteriosclerosis"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0580","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclo-oxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.therap.2018.11.002_bib0585","first-page":"664","article-title":"Heart Failure after phenylbutazone treatment","volume":"74","author":"Cullhed","year":"1965","journal-title":"Nord Med"},{"key":"10.1016\/j.therap.2018.11.002_bib0590","first-page":"99","article-title":"Aspects of the effects of NSAID's on renal function in congestive heart failure","volume":"17","author":"Eriksson","year":"1985","journal-title":"Agents Actions Suppl"},{"issue":"2B","key":"10.1016\/j.therap.2018.11.002_bib0595","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0002-9343(86)90913-7","article-title":"Prostaglandins in congestive heart failure and the effects of non-steroidal anti-inflammatory drugs","volume":"81","author":"Cannon","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2018.11.002_bib0600","first-page":"1061","article-title":"Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs","volume":"11","author":"Moore","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.therap.2018.11.002_bib0605","doi-asserted-by":"crossref","first-page":"i4857","DOI":"10.1136\/bmj.i4857","article-title":"Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study","volume":"354","author":"Arfe","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2018.11.002_bib0610","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000401652","article-title":"Prostaglandins and renal function","volume":"12","author":"McGiff","year":"1978","journal-title":"Contrib Nephrol"},{"issue":"3","key":"10.1016\/j.therap.2018.11.002_bib0615","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10787-999-0015-y","article-title":"Cardiac and renal failure due to NSAIDs: a review of the epidemiological literature","volume":"7","author":"Henry","year":"1999","journal-title":"Inflammopharmacology"},{"issue":"6","key":"10.1016\/j.therap.2018.11.002_bib0620","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/adc.2006.103564","article-title":"Using NSAID in volume depleted children can precipitate acute renal failure","volume":"92","author":"John","year":"2007","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0625","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/oxfordjournals.aje.a010234","article-title":"Non-steroidal antiinflammatory drugs and acute renal failure in elderly persons","volume":"151","author":"Griffin","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.therap.2018.11.002_bib0630","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.clinthera.2006.08.014","article-title":"Hepatic disorders in patients treated with COX-2 selective inhibitors or non-selective NSAIDs: a case\/noncase analysis of spontaneous reports","volume":"28","author":"Sanchez-Matienzo","year":"2006","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.therap.2018.11.002_bib0635","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","article-title":"A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience","volume":"15","author":"Goldkind","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2018.11.002_bib0640","doi-asserted-by":"crossref","first-page":"5253623","DOI":"10.1155\/2018\/5253623","article-title":"Hepatotoxicity of non-steroidal anti-inflammatory drugs: a systematic review of randomized controlled trials","volume":"2018","author":"Sriuttha","year":"2018","journal-title":"Int J Hepatol"},{"issue":"2 Pt 1","key":"10.1016\/j.therap.2018.11.002_bib0645","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0190-9622(86)80342-5","article-title":"Toxic epidermal necrolysis after oxicam use","volume":"14","author":"Penso","year":"1986","journal-title":"J Am Acad Dermatol"},{"issue":"8453","key":"10.1016\/j.therap.2018.11.002_bib0650","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(85)90426-X","article-title":"Fatal epidermal necrolysis associated with isoxicam","volume":"2","author":"Flechet","year":"1985","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.therap.2018.11.002_bib0655","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2230.1982.tb02428.x","article-title":"Toxic epidermal necrolysis, leucopenia and thrombocytopenic purpura--a further complication of Benoxaprofen therapy","volume":"7","author":"Fenton","year":"1982","journal-title":"Clin Exp Dermatol"},{"issue":"8257","key":"10.1016\/j.therap.2018.11.002_bib0660","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(81)91467-7","article-title":"Photosensitization to benoxaprofen not due to ultraviolet A alone","volume":"2","author":"Fenton","year":"1981","journal-title":"Lancet"},{"issue":"6326","key":"10.1016\/j.therap.2018.11.002_bib0665","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/bmj.284.6326.1365","article-title":"side-effect profile in 300 patients","volume":"284","author":"Halsey","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"10.1016\/j.therap.2018.11.002_bib0670","first-page":"124","article-title":"Phototoxicity to benoxaprofen","volume":"5","author":"Kligman","year":"1982","journal-title":"Eur J Rheumatol Inflamm"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0675","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0190-9622(82)70151-3","article-title":"Benoxaprofen-induced photo-onycholysis","volume":"7","author":"McCormack","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.therap.2018.11.002_bib0680","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00002018-200022050-00002","article-title":"Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data","volume":"22","author":"Bagheri","year":"2000","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.therap.2018.11.002_bib0685","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1684\/ejd.2014.2332","article-title":"Serious photocontact dermatitis induced by topical ketoprofen depends on the formulation","volume":"24","author":"Guy","year":"2014","journal-title":"Eur J Dermatol"},{"issue":"7","key":"10.1016\/j.therap.2018.11.002_bib0690","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00204-006-0063-7","article-title":"Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig","volume":"80","author":"Nakazawa","year":"2006","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.therap.2018.11.002_bib0695","first-page":"CD007400","article-title":"Topical NSAIDs for chronic musculoskeletal pain in adults","volume":"4","author":"Derry","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2018.11.002_bib0700","first-page":"CD007402","article-title":"Topical NSAIDs for acute musculoskeletal pain in adults","volume":"6","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:16Z","timestamp":1758567196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718302476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0040595718302476"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.11.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacoepidemiology of non-steroidal anti-inflammatory drugs","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}